Candriam Luxembourg S.C.A. Has $4.82 Million Stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Candriam Luxembourg S.C.A. boosted its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 12.7% during the second quarter, according to its most recent filing with the SEC. The firm owned 293,000 shares of the biopharmaceutical company’s stock after buying an additional 33,000 shares during the period. Candriam Luxembourg S.C.A. owned approximately 0.28% of Lexicon Pharmaceuticals worth $4,820,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the stock. Moody Aldrich Partners LLC boosted its stake in shares of Lexicon Pharmaceuticals by 37.7% in the second quarter. Moody Aldrich Partners LLC now owns 30,930 shares of the biopharmaceutical company’s stock worth $509,000 after buying an additional 8,475 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Lexicon Pharmaceuticals during the first quarter worth about $5,485,000. Credit Suisse AG boosted its stake in shares of Lexicon Pharmaceuticals by 27.5% in the first quarter. Credit Suisse AG now owns 92,548 shares of the biopharmaceutical company’s stock worth $1,327,000 after buying an additional 19,978 shares during the last quarter. Paloma Partners Management Co boosted its stake in shares of Lexicon Pharmaceuticals by 22.5% in the first quarter. Paloma Partners Management Co now owns 70,672 shares of the biopharmaceutical company’s stock worth $1,013,000 after buying an additional 12,967 shares during the last quarter. Finally, Highbridge Capital Management LLC bought a new position in Lexicon Pharmaceuticals during the first quarter valued at $7,813,000.

Shares of Lexicon Pharmaceuticals, Inc. (LXRX) traded up 0.48% on Thursday, hitting $14.58. 324,596 shares of the stock traded hands. The stock’s market cap is $1.54 billion. Lexicon Pharmaceuticals, Inc. has a 52 week low of $13.41 and a 52 week high of $19.62. The stock has a 50 day moving average price of $15.93 and a 200-day moving average price of $15.44.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The company had revenue of $12 million for the quarter, compared to analyst estimates of $18.34 million. During the same quarter in the previous year, the firm posted ($0.37) earnings per share. The company’s quarterly revenue was down 40.3% compared to the same quarter last year. On average, equities research analysts forecast that Lexicon Pharmaceuticals, Inc. will post ($1.45) EPS for the current year.

Several research firms have weighed in on LXRX. ValuEngine raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. BidaskClub raised shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, June 14th. Zacks Investment Research cut shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 5th. Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, August 1st. Finally, HC Wainwright set a $27.00 price target on shares of Lexicon Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 3rd. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $27.00.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.